Toward Minimal Residual Disease-Directed Therapy in Melanoma

Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel Brown, Young Hwan Chang, Maria Debiec-Rychter, Carmen Adriaens, Enrico Radaelli, Pascal Wolter, Oliver Bechter, Reinhard Dummer, Mitchell Levesque, Adriano Piris, Dennie T. Frederick, Genevieve Boland, Keith T. Flaherty & 5 others Joost van den Oord, Thierry Voet, Stein Aerts, Amanda Lund, Jean Christophe Marine

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs from PDXs and biopsies of patients on treatment. One of these exhibited a neural crest stem cell (NCSC) transcriptional program largely driven by the nuclear receptor RXRG. An RXR antagonist mitigated accumulation of NCSCs in MRD and delayed the development of resistance. These data identify NCSCs as key drivers of resistance and illustrate the therapeutic potential of MRD-directed therapy. They also highlight how gene regulatory network architecture reprogramming may be therapeutically exploited to limit cellular heterogeneity, a key driver of disease progression and therapy resistance. Drug-tolerant cells that persist through treatment of melanoma exhibit multiple transcriptional states, one of which is a key driver that can be targeted therapeutically.

Original languageEnglish (US)
Pages (from-to)843-855.e19
JournalCell
Volume174
Issue number4
DOIs
StatePublished - Aug 9 2018

Fingerprint

Residual Neoplasm
Melanoma
Therapeutics
Biopsy
RNA Sequence Analysis
Mitogen-Activated Protein Kinase Kinases
Cytoplasmic and Nuclear Receptors
Stem cells
Network architecture
Neural Stem Cells
Heterografts
Neural Crest
Gene Regulatory Networks
Pharmaceutical Preparations
Genes
Disease Progression
RNA
Recurrence
Neoplasms

Keywords

  • cutaneous melanoma
  • drug tolerance
  • gene regulatory networks
  • RXR signaling
  • single cell transcriptomics
  • targeted therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., ... Marine, J. C. (2018). Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, 174(4), 843-855.e19. https://doi.org/10.1016/j.cell.2018.06.025

Toward Minimal Residual Disease-Directed Therapy in Melanoma. / Rambow, Florian; Rogiers, Aljosja; Marin-Bejar, Oskar; Aibar, Sara; Femel, Julia; Dewaele, Michael; Karras, Panagiotis; Brown, Daniel; Chang, Young Hwan; Debiec-Rychter, Maria; Adriaens, Carmen; Radaelli, Enrico; Wolter, Pascal; Bechter, Oliver; Dummer, Reinhard; Levesque, Mitchell; Piris, Adriano; Frederick, Dennie T.; Boland, Genevieve; Flaherty, Keith T.; van den Oord, Joost; Voet, Thierry; Aerts, Stein; Lund, Amanda; Marine, Jean Christophe.

In: Cell, Vol. 174, No. 4, 09.08.2018, p. 843-855.e19.

Research output: Contribution to journalArticle

Rambow, F, Rogiers, A, Marin-Bejar, O, Aibar, S, Femel, J, Dewaele, M, Karras, P, Brown, D, Chang, YH, Debiec-Rychter, M, Adriaens, C, Radaelli, E, Wolter, P, Bechter, O, Dummer, R, Levesque, M, Piris, A, Frederick, DT, Boland, G, Flaherty, KT, van den Oord, J, Voet, T, Aerts, S, Lund, A & Marine, JC 2018, 'Toward Minimal Residual Disease-Directed Therapy in Melanoma', Cell, vol. 174, no. 4, pp. 843-855.e19. https://doi.org/10.1016/j.cell.2018.06.025
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. 2018 Aug 9;174(4):843-855.e19. https://doi.org/10.1016/j.cell.2018.06.025
Rambow, Florian ; Rogiers, Aljosja ; Marin-Bejar, Oskar ; Aibar, Sara ; Femel, Julia ; Dewaele, Michael ; Karras, Panagiotis ; Brown, Daniel ; Chang, Young Hwan ; Debiec-Rychter, Maria ; Adriaens, Carmen ; Radaelli, Enrico ; Wolter, Pascal ; Bechter, Oliver ; Dummer, Reinhard ; Levesque, Mitchell ; Piris, Adriano ; Frederick, Dennie T. ; Boland, Genevieve ; Flaherty, Keith T. ; van den Oord, Joost ; Voet, Thierry ; Aerts, Stein ; Lund, Amanda ; Marine, Jean Christophe. / Toward Minimal Residual Disease-Directed Therapy in Melanoma. In: Cell. 2018 ; Vol. 174, No. 4. pp. 843-855.e19.
@article{d16ebac078474a51b3358a345f0e80b0,
title = "Toward Minimal Residual Disease-Directed Therapy in Melanoma",
abstract = "Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs from PDXs and biopsies of patients on treatment. One of these exhibited a neural crest stem cell (NCSC) transcriptional program largely driven by the nuclear receptor RXRG. An RXR antagonist mitigated accumulation of NCSCs in MRD and delayed the development of resistance. These data identify NCSCs as key drivers of resistance and illustrate the therapeutic potential of MRD-directed therapy. They also highlight how gene regulatory network architecture reprogramming may be therapeutically exploited to limit cellular heterogeneity, a key driver of disease progression and therapy resistance. Drug-tolerant cells that persist through treatment of melanoma exhibit multiple transcriptional states, one of which is a key driver that can be targeted therapeutically.",
keywords = "cutaneous melanoma, drug tolerance, gene regulatory networks, RXR signaling, single cell transcriptomics, targeted therapy",
author = "Florian Rambow and Aljosja Rogiers and Oskar Marin-Bejar and Sara Aibar and Julia Femel and Michael Dewaele and Panagiotis Karras and Daniel Brown and Chang, {Young Hwan} and Maria Debiec-Rychter and Carmen Adriaens and Enrico Radaelli and Pascal Wolter and Oliver Bechter and Reinhard Dummer and Mitchell Levesque and Adriano Piris and Frederick, {Dennie T.} and Genevieve Boland and Flaherty, {Keith T.} and {van den Oord}, Joost and Thierry Voet and Stein Aerts and Amanda Lund and Marine, {Jean Christophe}",
year = "2018",
month = "8",
day = "9",
doi = "10.1016/j.cell.2018.06.025",
language = "English (US)",
volume = "174",
pages = "843--855.e19",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Toward Minimal Residual Disease-Directed Therapy in Melanoma

AU - Rambow, Florian

AU - Rogiers, Aljosja

AU - Marin-Bejar, Oskar

AU - Aibar, Sara

AU - Femel, Julia

AU - Dewaele, Michael

AU - Karras, Panagiotis

AU - Brown, Daniel

AU - Chang, Young Hwan

AU - Debiec-Rychter, Maria

AU - Adriaens, Carmen

AU - Radaelli, Enrico

AU - Wolter, Pascal

AU - Bechter, Oliver

AU - Dummer, Reinhard

AU - Levesque, Mitchell

AU - Piris, Adriano

AU - Frederick, Dennie T.

AU - Boland, Genevieve

AU - Flaherty, Keith T.

AU - van den Oord, Joost

AU - Voet, Thierry

AU - Aerts, Stein

AU - Lund, Amanda

AU - Marine, Jean Christophe

PY - 2018/8/9

Y1 - 2018/8/9

N2 - Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs from PDXs and biopsies of patients on treatment. One of these exhibited a neural crest stem cell (NCSC) transcriptional program largely driven by the nuclear receptor RXRG. An RXR antagonist mitigated accumulation of NCSCs in MRD and delayed the development of resistance. These data identify NCSCs as key drivers of resistance and illustrate the therapeutic potential of MRD-directed therapy. They also highlight how gene regulatory network architecture reprogramming may be therapeutically exploited to limit cellular heterogeneity, a key driver of disease progression and therapy resistance. Drug-tolerant cells that persist through treatment of melanoma exhibit multiple transcriptional states, one of which is a key driver that can be targeted therapeutically.

AB - Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs from PDXs and biopsies of patients on treatment. One of these exhibited a neural crest stem cell (NCSC) transcriptional program largely driven by the nuclear receptor RXRG. An RXR antagonist mitigated accumulation of NCSCs in MRD and delayed the development of resistance. These data identify NCSCs as key drivers of resistance and illustrate the therapeutic potential of MRD-directed therapy. They also highlight how gene regulatory network architecture reprogramming may be therapeutically exploited to limit cellular heterogeneity, a key driver of disease progression and therapy resistance. Drug-tolerant cells that persist through treatment of melanoma exhibit multiple transcriptional states, one of which is a key driver that can be targeted therapeutically.

KW - cutaneous melanoma

KW - drug tolerance

KW - gene regulatory networks

KW - RXR signaling

KW - single cell transcriptomics

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85049472211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049472211&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.06.025

DO - 10.1016/j.cell.2018.06.025

M3 - Article

VL - 174

SP - 843-855.e19

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -